Shares of clinical-stage biopharma Curis, Inc. (NASDAQ: CRIS) dropped over 14% this morning after the company released second-quarter 2017 financial results and provided an update on a phase 2 trial. The company’s most advanced drug candidate, CUDC-907, did not deliver results that will allow for accelerated approval — a goal that influenced the phase 2 trial’s design in the first place — in treating diffuse large B-cell lymphoma, or DLBCL, with specific genetic mutations.